AmoyDx Signs Memorandum with AstraZeneca to Cooperate in Molecular Diagnostics in Gynecological Oncology worldwide
Time:2020-11-16Source : AmoyDx
Xiamen, China, 16th November, 2020 – Recently Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685) signed a collaborative memorandum with AstraZeneca in the third China International Import Expo.
 
For over ten years, AmoyDx is a long-term strategic partner of AstraZeneca. Both parties worked together closely with well-known experts to advance the development of lung cancer diagnostics in China, which has benefitted millions of lung cancer patients. Nowadays, AmoyDx and AstraZeneca would work together in the field of gynecological oncology and expand the cooperation beyond China to many countries in the world. This strategic collaboration will benefit gynecological cancer patients that often have homologous recombination repair (HRR)/homologous recombination defects (HRD) that play an important role in the development of cancer and where drugs such as PARP inhibitors may help.
 
As a company specialized in the development of test kits for the molecular diagnosis in oncology, AmoyDx always adheres to its goals to develop products that are highly innovative. Being the leading molecular diagnostics company in China, AmoyDx is a diagnostics partner of many pharmaceutical companies. Currently, the company has more than 20 products approved by Chinese Health Authority NMPA as companion diagnostics, covering most types of cancer where patients can benefit from targeted treatment based on molecular diagnosis. Meanwhile, over 20 diagnostic products are CE marked in Europe.
 
AmoyDx has created awareness of the importance of molecular diagnostics by cooperating with partners worldwide, especially in lung cancer, colorectal cancer and gynecological cancer. In the future, AmoyDx will continue to provide high-quality, innovative products to meet the demands of precision oncology and to benefit cancer patients worldwide.
 
About PARP inhibitors:
PARP inhibitors, a cancer therapy targeting the poly (ADP-ribose) polymerase, are the first clinically approved drugs designed to exploit synthetic lethality, Currently, PARP inhibitors have been approved to treat breast, ovarian, pancreatic and prostate cancers. The use of PARP inhibitors greatly improved the patient’s survival. The SOLO1 trial demonstrated that in patients with BRCA-mutated advanced ovarian cancer following first-line platinum-based chemotherapy, a statistically significant improvement in investigator-assessed progression-free survival (PFS) could be observed for olaparib compared to placebo. At the time of data analysis, the estimated median PFS was not reached in the olaparib arm and was 13.8 months in the placebo arm (HR 0.30; 95% CI: 0.23-0.41; p<0.0001). The POLO trial demonstrated that among patients with a germline BRCA mutation and metastatic pancreatic cancer, PFS was longer with maintenance olaparib than with placebo (7.4 months vs. 3.8 months; HR, 0.53; 95% CI: 0.35 to 0.82; P=0.004).
 
About HRR/HRD:

Homologous recombination (HR) plays a pivotal role in maintaining genomic stability by repairing complex DNA damage such as DNA double-stranded breaks and interstream cross-links. When the HR pathway is disrupted by gene mutations, promoter methylation or unidentified causes, the HR pathway stops working leading to HRD, tumors with HRD are unable to repair themselves after sustaining damage leading to genomic instability. Most HRD tumors are sensitive to platinum or PARP inhibition therapy, therefore, HRR/HRD testing can be used to predict response to PARP inhibitors.

 

For more information, please call us at +86-592-6892985 or email us at info@amoydx.com.



Tel:+86-592-6892985
Email:info@amoydx.com
BACK
TOP
Inquiry
* Required information
Manage your account info
Change your password